Viewing Study NCT03964792

Home

Certify Doc

Genes

Clinical Trials

CompTox

DrugMatrix

Open Targets

Products

Support

Bugs

Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug

Ignite Creation Date: 2025-12-24 @ 3:28 PM

Ignite Modification Date: 2025-12-26 @ 10:21 PM

Study NCT ID: NCT03964792

Status: ACTIVE_NOT_RECRUITING

Last Update Posted: 2024-01-09

First Post: 2019-05-14

Is NOT Gene Therapy: True

Has Adverse Events: False

Brief Title: Safety and Efficacy of Gene Therapy of the Sickle Cell Disease by Transplantation of an Autologous CD34+ Enriched Cell Fraction That Contains CD34+ Cells Transduced ex Vivo With the GLOBE1 Lentiviral Vector Expressing the βAS3 Globin Gene in Patients With Sickle Cell Disease (DREPAGLOBE)

Sponsor: Assistance Publique - Hôpitaux de Paris

Organization:

Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module